2022
DOI: 10.1039/d2an00094f
|View full text |Cite
|
Sign up to set email alerts
|

Secretory expression and purification of recombinant PLA2R epitopes for the detection of anti-PLA2R autoantibody in serum

Abstract: Most patients with idiopathic membranous nephropathy (IMN) have autoimmune antibodies specifically against the M-type phospholipase A2 receptor (PLA2R). PLA2R acts as a significant biomarker contributing to the clinical diagnosis of...

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 28 publications
0
3
0
Order By: Relevance
“…In order to confirm the interaction between recombinant AQP4-DARPins and serum AQP4-IgG, we used indirect ELISA to confirm whether AQP4-DARPins are effectively recognized by serum AQP4-IgG and further identified whether serum AQP4-IgG can bind with AQP4-DARPins by IP. , In the AQP4-IgG ELISA strategy, AQP4-DARPins were coated on microplates (Figure A). Subsequently, serum AQP4-IgG from NMOSD patients was captured by AQP4-DARPins and then recognized by HRP-labeled mouse antihuman IgG.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In order to confirm the interaction between recombinant AQP4-DARPins and serum AQP4-IgG, we used indirect ELISA to confirm whether AQP4-DARPins are effectively recognized by serum AQP4-IgG and further identified whether serum AQP4-IgG can bind with AQP4-DARPins by IP. , In the AQP4-IgG ELISA strategy, AQP4-DARPins were coated on microplates (Figure A). Subsequently, serum AQP4-IgG from NMOSD patients was captured by AQP4-DARPins and then recognized by HRP-labeled mouse antihuman IgG.…”
Section: Resultsmentioning
confidence: 99%
“…The AQP4-IgG ELISA was performed as previously described with slight modifications. 37 First, the recombinant AQP4-DARPins were diluted in coating (PBS) buffer: 10 mM sodium phosphate, pH 7.4, 150 mM NaCl, and then coated on a 96-well microplate (100 μL per well) at 25 °C for 2 h. The plate was then washed with PBST (0.05% v/v Tween-20 in PBS) five times and blocked with blocking buffer (1% m/v BSA in PBS, 200 μL per well) at 25 °C for 2 h. Next, the serum from NMOSD patients and other AID patients was added (50 μL per well), while the serum from healthy individuals was used as a negative control. The plate was then incubated at 25 °C for 1 h and washed with PBST five times.…”
Section: ■ Materials and Methodsmentioning
confidence: 99%
“…Expression and purification of S100B protein were performed as described previously. 24,25 Briefly, based on the genome sequence of S100B (NCBI reference sequence: NP_006263.1), a codon-optimized gene was designed and synthesized by Genecefe Biotechnology Co., Ltd (Wuxi, China). The fragment was then cloned into the expression vector pCMV3.…”
Section: Production Of Monoclonal Antibodies Against S100bmentioning
confidence: 99%